Patients who have had an echocardiogram performed within  months prior to step  randomization must have ventricular ejection fraction (left ventricular ejection fraction [LVEF]) >= % or >= within normal limits for the institution
Patients must have ejection fraction >= % based on echocardiogram performed within  days prior to registration
Transthoracic echocardiogram with ejection fraction > %
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= % by echocardiogram =<  days prior to registration
Left ventricular ejection fraction (LVEF) >= % calculated by echocardiogram (ECHO)
PART I: Baseline left ventricular ejection fraction (LVEF) by  dimensional (D) echocardiogram >= %
Echocardiogram demonstrated left ventricular ejection fraction >= %.
Left ventricular ejection fraction < % as measured on transthoracic echocardiogram
Left ventricular ejection fraction (LVEF) < % as assessed by echocardiogram or radionuclide angiography
Within two weeks prior to enrollment: Left ventricular ejection fraction (LVEF) >= % as determined an echocardiogram
Left ventricular ejection fraction (LVEF) < % as assessed by echocardiogram or radionuclide angiography
Echocardiogram demonstrating left ventricular ejection fraction (LVEF) >= %
Left ventricular ejection fraction (LVEF) ejection fraction (EF) >= of % (by echocardiogram or MUGA scan within  weeks of registration), within  weeks of registration (except where specified otherwise)
Left ventricular ejection fraction (LVEF) < % as assessed by echocardiogram or radionuclide angiography
Have a -dimensional (D) echocardiogram with left ventricular ejection fraction = or > % in order to receive epirubicin; subjects with inadequate ejection fraction (EF) or other contraindication can proceed on study without the use of epirubicin
Patients with left ventricular ejection fraction < % or % decrease from baseline on echocardiogram after anthracycline based chemotherapy
Left ventricular ejection fraction (LVEF) assessed by echocardiogram within  months prior to initiation of study treatment indicates an LVEF of >= %
Left ventricular ejection fraction (LVEF) < % (evaluated by echocardiogram or magnetic resonance imaging [MRI])
Left ventricular ejection fraction: < % estimated by echocardiogram (ECHO)
RECIPIENT: Left ventricular ejection fraction > %, preferably by -dimensional (-D) echocardiogram (echo) obtained within  days of enrollment
Left ventricular ejection fraction > %, preferably by two dimensional (-D) echocardiogram (ECHO), obtained within  days of enrollment; if the patient has radiological evidence of aortic, renal artery, or coronary artery vasculitis, a left ventricular ejection fraction > % is acceptable
Normal echocardiogram (ECHO) (Left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)
Left ventricular ejection fraction (LVEF) >= % as measured by echocardiogram during screening evaluation
Echocardiogram with normal ejection fractions
Symptomatic congestive heart failure or radionuclide ventriculogram (RVG) or echocardiogram determined left ventricular ejection fraction of < %, active angina pectoris, or uncontrolled hypertension
Within  days of registration: Left ventricular ejection fraction (echocardiogram within  months permitted) >= %
Subjects who have a left ventricular ejection fraction (LVEF) < %, as assessed by echocardiogram performed at screening
Patients must have either echocardiogram (ECHO) with ejection fraction >= % within  days prior to registration
Normal echocardiogram (ECHO) (left ventricular ejection fraction [LVEF] has to be within normal, institutional limits)
Left Ventricular Shortening Fraction (LVSF) ? % confirmed by echocardiogram, or Left Ventricular Ejection Fraction (LVEF) ? % confirmed by echocardiogram or MUGA within  days of screening
Hemodynamically stable and Left Ventricle Ejection Fraction (LVEF) ? % confirmed by echocardiogram or Multigated Radionuclide Angiography (MUGA)
Symptomatic congestive heart failure or evidence of left ventricular dysfunction (ejection fraction < %) as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension
Active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained the left ventricular ejection fraction (LVEF) should exceed %
Baseline ejection fraction ? % as assessed by echocardiogram or MUGA.
PHASE II: Left ventricular ejection fraction (LVEF) >= % calculated by echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) of at least % as determined by MUGA or echocardiogram
Baseline (<  month before treatment) cardiac left ventricular function with resting ejection fraction of less than % measured by echocardiogram
Left ventricular ejection fraction (LVEF) < % as assessed by echocardiogram or radionuclide angiography
Left ventricular ejection fraction >= %, as determined by radionuclide ventriculography (RVG) or echocardiogram within  days prior to initiation of protocol therapy
Left ventricular ejection fraction >= %, as determined by RVG (MUGA) or echocardiogram within  days prior to initiation of extension phase therapy (all cohorts)
Active symptomatic ischemic heart disease, myocardial infarction or congestive heart failure within the past year; if echocardiogram (ECHO) is obtained, the left ventricular ejection fraction (LVEF) should exceed %
Left ventricular ejection fraction <% as determined by echocardiogram (ECHO) performed at screening or within  days prior to CD
Adequate heart function with echocardiogram demonstrating ejection fraction >= % with no evidence of systolic dysfunction
Baseline cardiac echocardiogram scan with left ventricular ejection fraction (LVEF) of >= %
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Cardiac function: \r\n* Left ventricular ejection fraction >=  by gated radionuclide study OR shortening fraction of >= % by echocardiogram\r\n* Patient has no ventricular arrhythmias except for benign premature ventricular contractions\r\n* Patient has a corrected QT (QTc) interval =<  ms
Patients with a left ventricular cardiac ejection fraction < % as assessed by an echocardiogram or MUGA scan
Left ventricular ejection fraction < % as assessed by echocardiogram or radionuclide angiography.
Subjects with a left ventricular cardiac ejection fraction < % as assessed by an echocardiogram or MUGA scan
Left ventricular ejection fraction (LVEF) ?% by echocardiogram
Left ventricular ejection fraction (LVEF) <%, as determined by screening echocardiogram (echocardiogram results obtained within  days prior to screening are acceptable)
Left ventricular ejection fraction (LVEF) < % by MUGA or echocardiogram
Adequate cardiac function measured by left ventricular ejection fraction (LVEF) > %; if asymptomatic, pre-transplant echocardiogram is adequate; if symptomatic, echocardiogram needs to be repeated
Spirometry with at least % of predicted volumes (including FEV). A left ventricular ejection fraction (LVEF) of % or more. All patients will have a screening -D Echocardiogram as part of eligibility screening.
MUGA/Echocardiogram Left Ventricular Ejection Fraction < %.
If in Arm D (doxorubicin and cyclophosphamide), left ventricular ejection fraction (LVEF) >= % as measured by echocardiogram (ECHO) within  weeks prior to study drug administration
Baseline screening echocardiogram (echo) left ventricular ejection fraction (LVEF) =< 
Left ventricular ejection fraction < % (evaluated by echocardiogram or MUGA scan)
Left ventricular ejection fraction < % (evaluated by echocardiogram or MUGA)
